|
|
 Previous Article | Table of Contents | Next Article 
T Helper 2-Dominant Antilymphoma Immune Response Is Associated With Fatal Outcome
Peter P. Lee,
Defu Zeng,
Ann E. McCaulay,
Yan-Fei Chen,
Craig Geiler,
Dale T. Umetsu, and
Nelson J. Chao
From the Department of Medicine, Divisions of Bone Marrow Transplantation and Immunology, and the Department of Pediatrics, Stanford University Medical Center, Stanford, CA.
The precise role of the endogenous immune system in modulating cancer development remains unclear. Tumor cells are generally thought to be nonimmunogenic because they are of `self' origin. However, tumor-reactive lymphocytes can be isolated from patients with many types of cancer. It is unclear what role these lymphocytes play and why they fail to protect the host. Using a murine B-cell leukemia/lymphoma (BCL1) model, we showed the development of a vigorous antitumor T-cell response in the tumor-susceptible host. Specific T-cell responses against BCL1 developed as early as day 4. However, the nature of this nonprotective response is different from the protective response produced in a major histocompatibility complex-matched tumor-resistant host. Susceptible hosts developed a T helper 2 (Th2)-dominant response, whereas resistant hosts developed a Th1-dominant response to BCL1. Cytolytic activity against BCL1 developed in both resistant and susceptible hosts, but in the susceptible host, this response was weaker and delayed compared with that in the resistant host. Thus, tumor susceptibility does not necessarily mean the absence of an antitumor immune response. Rather, the nature of the antitumor immune response is critical in determining clinical outcome.
Blood, Vol. 90 No. 4 (August 15), 1997:
pp. 1611-1617
© 1997 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
K. Ait-Tahar, M. C.N. Barnardo, and K. Pulford
CD4 T-Helper Responses to the Anaplastic Lymphoma Kinase (ALK) Protein in Patients with ALK-Positive Anaplastic Large-Cell Lymphoma
Cancer Res.,
March 1, 2007;
67(5):
1898 - 1901.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Wong, R. Lau, J. Chang, T. Kuus-Reichel, V. Brichard, C. Bruck, and J. Weber
Immune Responses to a Class II Helper Peptide Epitope in Patients with Stage III/IV Resected Melanoma
Clin. Cancer Res.,
August 1, 2004;
10(15):
5004 - 5013.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Conticello, F. Pedini, A. Zeuner, M. Patti, M. Zerilli, G. Stassi, A. Messina, C. Peschle, and R. De Maria
IL-4 Protects Tumor Cells from Anti-CD95 and Chemotherapeutic Agents via Up-Regulation of Antiapoptotic Proteins
J. Immunol.,
May 1, 2004;
172(9):
5467 - 5477.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Huang and L. D. Hazlett
Analysis of Pseudomonas aeruginosa Corneal Infection Using an Oligonucleotide Microarray
Invest. Ophthalmol. Vis. Sci.,
August 1, 2003;
44(8):
3409 - 3416.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. J. Chen, X. Cui, C. Liu, and N. J. Chao
Prevention of graft-versus-host disease while preserving graft-versus-leukemia effect after selective depletion of host-reactive T cells by photodynamic cell purging process
Blood,
May 1, 2002;
99(9):
3083 - 3088.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Holliger, O. Manzke, M. Span, R. Hawkins, B. Fleischmann, L. Qinghua, J. Wolf, V. Diehl, O. Cochet, G. Winter, et al.
Carcinoembryonic Antigen (CEA)-specific T-Cell Activation in Colon Carcinoma Induced by Anti-CD3Anti-CEA Bispecific Diabodies and B7Anti-CEA Bispecific Fusion Proteins
Cancer Res.,
June 1, 1999;
59(12):
2909 - 2916.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Shimizu, K.-i. Inada, H. Nakanishi, T. Tsukamoto, Y. Ikehara, M. Kaminishi, S. Kuramoto, A. Sugiyama, T. Katsuyama, and M. Tatematsu
Helicobacter pylori infection enhances glandular stomach carcinogenesis in Mongolian gerbils treated with chemical carcinogens
Carcinogenesis,
April 1, 1999;
20(4):
669 - 676.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
